Skip Navigation LinksHome > January 2014 - Volume 33 - Issue > African Rotavirus Surveillance Network: A Brief Overview
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0000000000000174
Supplement

African Rotavirus Surveillance Network: A Brief Overview

Mwenda, Jason M. PhD*; Tate, Jacqueline E. PhD; Parashar, Umesh D. MB BS, MPH; Mihigo, Richard MD, MPH*; Agócs, Mary MD; Serhan, Fatima PhD; Nshimirimana, Deo MD, PhD*

Free Access
Article Outline
Collapse Box

Author Information

From the *World Health Organization, Regional Office for Africa, Brazzaville, Republic of Congo; National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA; and World Health Organization, Geneva, Switzerland.

Accepted for publication October 21, 2013.

The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention and World Health Organization.

The authors have no conflicts of interest to disclose. Financial support listed in the Acknowledgments.

Address for correspondence: Dr Jason M. Mwenda, New Vaccines Surveillance Officer, Immunization, Vaccines and Emergencies Cluster, WHO Regional Office for Africa, PO Box 06 Djoue, Brazzaville, Republic of Congo. E-mail: mwendaj@who.int.

Collapse Box

Abstract

With the imminent availability of new and prospective rotavirus vaccines, reliable information on burden of rotavirus diseases in the different African countries was required to enable evidence-based decision making regarding introduction of rotavirus vaccines. World Health Organization has been supporting Member States since 2006 to establish sentinel surveillance for rotavirus diarrhea in children <5 years of age using standardized guidelines. African countries are using this platform to generate high quality country specific data to document and demonstrate the burden of rotavirus gastroenteritis. The data gathered are being used by policy makers to guide decisions on appropriate intervention strategies for diarrhea control including the value and timing of the introduction of new rotavirus vaccines in the national immunization programs.

The World Health Organization (WHO) Regional Office for Africa has been supporting Ministries of Health to establish, strengthen and expand surveillance for diseases targeted by new vaccines as part of implementation of the Global Framework for Immunization, Monitoring and Surveillance and regional Integrated Disease Surveillance and Response.1,2 As part of this initiative, the African Rotavirus Surveillance Network was established in 2006 to generate country- and region-specific data on the burden of rotavirus diarrhea, to characterize and document the circulating rotavirus strains. These data were anticipated to inform decisions on rotavirus vaccine introduction into national immunization programs. Where possible, rotavirus surveillance was integrated with the surveillance for other vaccine preventable diseases including pediatric bacterial meningitis surveillance network that is similarly coordinated by WHO Regional Office for Africa.3 Hospital sites were selected based on defined criteria including those that cumulatively care for at least 100 children <5 years of age hospitalized for acute gastroenteritis per year. Also, hospital sites should have laboratory capabilities required to perform rotavirus diagnosis. WHO supports and contracts designated Rotavirus Regional Reference Laboratories and local universities to conduct regular training of participants from the network countries on rotavirus diagnostic techniques and good laboratory procedures as well as support regional external quality assurance and quality control programs. These RRLs also conduct rotavirus strain characterization to determine circulating rotavirus strains in the African region.

Over the past 7 years, the African Rotavirus Surveillance Network coordinated by WHO Regional Office for Africa has expanded from 4 sentinel sites located in 4 countries in 2006 to 34 sentinel sites located in 20 countries in 2012 (Fig. 1). Each of the participating sentinel hospitals conducts active surveillance for rotavirus diarrhea using a common surveillance protocol including case definition, laboratory techniques and data capture, sharing and analysis.4,5 Briefly, children who present to a sentinel hospital and meet the case definition [≥3 episodes of diarrhea (stools of a less formed character than usual) within a 24 hour period, <7 days before hospital visit, which is not explained by an underlying medical condition] are enrolled and a stool specimen collected. Basic demographic and clinical information is collected for every enrolled child. Stool specimens are tested by enzyme immunoassay at the sentinel hospital laboratories. A proportion of positive specimens are selected at random to represent all the months of the year and sent to RRLs for genotyping using RT-PCR.

FIGURE 1.
FIGURE 1.
Image Tools

From 2006 to 2012, a total of 42,693 children <5 years of age hospitalized for acute diarrhea in sentinel hospitals participating in the African Rotavirus Surveillance Network and reporting to WHO have been enrolled in the surveillance program (Table 1). Stool specimens were collected and tested from 38,950 (91%) of these children. The number of children enrolled annually has increased as the network has expanded over the last 7 years. A total of 15,313 (40.7%) specimens tested positive for rotavirus during the entire period with the percent positive ranging from 35.6% in 2008 to 49.1% in 2006.

TABLE 1.
TABLE 1.
Image Tools

Great variability in circulating rotavirus strains has been observed in African countries from year to year. G1P[8] was consistently the most prevalent rotavirus strain varying from 14% to 31% of all circulating strains, and mixed G and P strains were also commonly detected (12–14%) during 2009–2012 (Fig. 2). Strains, such as G2P[4], G3P[8] and G4P[8], which are routinely detected in developed countries are less common in Africa. Conversely, there are a number of strains including G1P[6], G2P[6], G3P[6], G1P [4], G9P[4], G12P[6] and G12P[8] commonly detected in the African region, accounting for 27–40% of circulating strains annually that are less common in developed countries. Notably, genotype P[8] was the most prevalent, followed by P[6] and P[4]. In this regard, it is reassuring that clinical trials of rotavirus vaccines in Africa found that the vaccine effectiveness was similar against vaccine and nonvaccine strains.6 However, it is important to continue monitoring the rotavirus strains circulating in various settings as great diversity of strains exists and not all aspects could be evaluated in the clinical trials.

FIGURE 2.
FIGURE 2.
Image Tools

The African Rotavirus Surveillance Network has played an important role in establishing the burden of rotavirus disease in Africa and the data have facilitated country decisions on rotavirus vaccine implementation. With the increased awareness of the local epidemiology of rotavirus diarrhea and the availability of rotavirus disease burden data contributed by the surveillance network, countries have begun to introduce rotavirus vaccines into their national immunization programs with financial support from GAVI. The rotavirus surveillance network is also adapting to meet local needs for monitoring the impact of the vaccine program.7,8 For example, Ghana and South Africa, the first countries in Africa to introduce rotavirus vaccines into their national immunization program are using rotavirus surveillance to monitor trends in rotavirus diarrhea pre- and postvaccine introduction as well as using their surveillance sites as a platform to evaluate rotavirus vaccine effectiveness.9 Similarly, Rwanda, which joined the network in 2010 and introduced rotavirus vaccine in May 2012, and Tanzania, which introduced vaccine in 2013, are also conducting a vaccine impact evaluation using established sentinel surveillance platforms.

As more countries in Africa introduce rotavirus vaccine, the network will continue to play an important role in monitoring the impact of vaccine and providing key data to policymakers, physicians, parents and pediatric associations to encourage and sustain the use of vaccine national immunization programs. This model using a surveillance program to generate data to facilitate, to sustain introduction of a new vaccine and to monitor the impact of newly introduced vaccine can be adapted as other new vaccines become available for use. Also, this network can serve as a platform at the country level to collect data on additional disease causing pathogens. For example, Ministry of Health, Zimbabwe has been using established sentinel surveillance for rotavirus to document Congenital Rubella Syndrome (CRS) disease burden since September 2011.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors acknowledge GAVI Alliance for financial support to WHO; support from national expanded program for immunization Managers; national Ministries of Health; WHO EPI/surveillance officers; Inter Country Support teams (IST) including the Data Managers and country sentinel site implementation teams coordinating rotavirus Surveillance at different levels and support from Centers for Disease Prevention and Control.

Back to Top | Article Outline

REFERENCES

1. World Health Organization Global Framework for Immunization, Monitoring and Surveillance (GFIMS). 2007; WHO/IVB/07.06

2. World Health Organization Technical Guidelines for Integrated Disease Surveillance and Response (IDSR) in the African Region. 2010; 2nd Ed WHO/AFRO

3. Standard Operating Procedures (SOPs) for rotavirus surveillance in Africa. 2010;

4. Generic Protocols for (i) Hospital-based Surveillance to Estimate the Burden of Rotavirus Gastroenteritis in Children and (ii) A Community-based Survey on Utilization of Health Care Services for Gastroenteritis in Children. 2002; Geneva World Health Organization

5. Mwenda JM, Ntoto KM, Abebe A, et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010; 202:(suppl)S5–S11

6. Steele AD, Neuzil KM, Cunliffe NA, et al. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012; 12:213

7. Zuber P, El-Ziq I, Kaddar M, et al. Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine. 2011; 29:3149–3154

8. World Health Organization Post-marketing Surveillance of Rotavirus Vaccine Safety. 2009; WHO/IVB/09.01;

9. Msimang VM, Page N, Groome MJ, et al. Impact of rotavirus vaccine on childhood diarrheal hospitalization following introduction into the South African public immunization program. Pediatr Infect Dis J. 2013;32:1358-1364.;

Copyright © 2013 by Lippincott Williams & Wilkins

Login